Skip to Main Content

Paper Details

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
BMJ Open Diabetes Res Care
10
2022
AD, Alzheimer's disease, MCI, Metformin, PD, Parkinson's disease, Type 2 diabetes, VD, dementia, diabetes, metformin, mild cognitive impairment, neurological conditions, patients, sulfonylurea, sulfonylureas, type 2 diabetes mellitus, vascular dementia
Author NameAffiliation
Danielle NewbyUniversity of Oxford
Danielle NewbyUniversity of Oxford
Danielle NewbyUniversity of Oxford
Danielle NewbyUniversity of Oxford
Lenore J LaunerNational Institute on Aging
Cornelia M van DuijnUniversity of Oxford
Cornelia M van Duijn
Cornelia M van DuijnUniversity of Oxford
Cornelia M van Duijn
  • 1 - 9

Datasets

Release 1.2